Completed NA INTERVENTIONAL 2-arm NCT05764811

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Mechanism of the Effect by Sodium-glucose Cotransporter-2 Inhibitor on Obesity Associated Cardiomyopathy

Sponsor: National Cheng-Kung University Hospital

Updated 5 times since 2023 Last updated: Feb 28, 2023 Started: Mar 6, 2020 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05764811, this NA trial focuses on Fatty Liver Disease and remains completed. Sponsored by National Cheng-Kung University Hospital, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Completed NA
Sep 2025 — Dec 2025 [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Apr 2023 — Jul 2024 [monthly]

Completed NA

First recorded

Mar 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cheng-Kung University Hospital

Data source: National Cheng-Kung University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tainan, Taiwan